Jack Wallace
Stock Analyst at Guggenheim
(3.20)
# 1,138
Out of 4,996 analysts
19
Total ratings
57.89%
Success rate
273.46%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $290.27 | -14.22% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $58.40 | -70.89% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $2.80 | +400.00% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $179.56 | +22.52% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $23.62 | +69.35% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $6.20 | +1,512.90% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $27.81 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $290.27
Upside: -14.22%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $58.40
Upside: -70.89%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $2.80
Upside: +400.00%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $179.56
Upside: +22.52%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $23.62
Upside: +69.35%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $6.20
Upside: +1,512.90%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $27.81
Upside: -